Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity

Yutaka Mori1, Yohta Itoh, Naoko Tajima

  • 1Department of Internal Medicine, National Hospital Organization, Utsunomiya National Hospital, Kawachi-gun, Tochigi, Japan. moriyutakajp@yahoo.com

Abstract

Insights

Telmisartan and valsartan reduced adipocyte size in diabetic rats. Telmisartan demonstrated a greater effect on adipocyte downsizing, likely due to PPAR-gamma activation.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Research

Background:

  • The renin-angiotensin system (RAS) plays a role in metabolic regulation.
  • Adipocyte size and number are critical in obesity and type 2 diabetes.

Purpose of the Study:

  • To compare the effects of telmisartan and valsartan on adipocyte cellularity.
  • To investigate the influence of renin-angiotensin system (RAS) blockade on adipocytes in a type 2 diabetic rat model.

Main Methods:

  • Otsuka Long Evans Tokushima Fatty rats were treated with valsartan, telmisartan, or amlodipine for 16 weeks.
  • Adipocyte cellularity was assessed via histopathologic examination.
  • Fasting plasma glucose and insulin levels were measured.

Main Results:

  • Telmisartan significantly reduced fasting insulin levels compared to controls.
  • Both valsartan and telmisartan decreased the ratio of large adipocytes and mean adipocyte size.
  • Telmisartan showed a more pronounced reduction in large adipocytes and mean adipocyte size than valsartan.

Conclusions:

  • Telmisartan and valsartan effectively reduce adipocyte size in this model.
  • Telmisartan exhibits superior adipocyte downsizing effects compared to valsartan.
  • Peroxisome proliferator-activated receptor gamma (PPAR-gamma) activation is a potential mechanism for telmisartan's enhanced effect.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.